Molnupiravir was developed for the treatment of Influenza. According to whistleblower complaint Molnupiravir has mutagenic properties and may change your DNA. Now, Molnupiravir has been repurposed for COVID-19. Merck has entered into agreements with Indian manufacturers and has also announced $5 million of donations to enter into Indian market. Here is all you need to know about Merck’s Covid pill Molnupiravir.
Once again, Big Pharma chooses something highly mutagenic.
Mutagenic means it damages cell DNA and can make cells carcinogenic.
” It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral RNA replication.
The drug was developed at Emory University by the university’s drug innovation company, Drug Innovation Ventures at Emory (DRIVE).
It was then acquired by Miami-based company Ridgeback Biotherapeutics, who later partnered with Merck & Co. to develop the drug further.”
h/t Uppity Me